AML |
adult acute myeloid leukemia |
APC |
antigen presenting cell |
ART-Ig |
asymmetric re-engineering technology—immunoglobulin |
ATTACK |
asymmetric tandem trimerbody for T cell activation and cancer killing |
B-ALL |
B cell acute lymphoblastic leukemia |
BBB |
blood-brain barrier |
BEAT |
bispecific engagement by antibodies based on the T cell receptor |
BiKE |
bispecific killer engager |
BiTE |
bispecific T-cell engager |
CAR |
chimeric antigen receptor |
CD |
cluster of differentiation |
CIKs |
cytokine-induced killers |
CLL |
chronic lymphocytic leukemia |
CNS |
central nervous system |
CR |
complete response |
CRS |
cytokine released syndrome |
CTL |
cytotoxic T lymphocytes |
DART |
dual affinity retargeting (antibody) |
DLBCL |
diffuse large B cell lymphoma |
DVD-Ig |
dual variable domain immunoglobulins |
EGFRt |
truncated version of epidermal growth factor receptor |
EMA |
European Medicines Agency |
EpCAM |
epithelial cell adhesion molecule |
Fc |
fragment, crystallizable |
FIT-Ig |
Fabs-in-tandem immunoglobulins |
GVH, GVHD |
graft-versus-host (disease) |
HC |
heavy chain |
HLA |
human leukocyte antigen |
HSV-TK |
herpes simplex virus thymidine kinase |
iCasp9 |
inducible caspase-9 |
Ig |
immunoglobulin |
ImmTAC |
immune-mobilizing monoclonal TCR against cancer |
iNKT |
invariant NKT (cells) |
ITAM |
immunoreceptor tyrosine activation motif |
KIH |
knobs-into-holes |
LC |
light chain |
MATH |
mutant-allele tumor heterogeneity |
MHC |
major histocompatibility complex |
MM |
multiple myeloma |
NK |
natural killer (cell) |
NKG2D |
natural killer group 2D |
NKT |
natural killer T (cell) |
NSCLC |
non-small cell lung cancer |
OR |
objective response |
PBMCs |
peripheral blood mononuclear cells |
pMHC |
peptide-MHC complex |
PR |
partial response |
R/R |
relapsed/refractory |
sCAR |
switchable chimeric antigen receptor |
scFv |
single chain, fragment variable |
SEED |
strand exchange engineered domain |
SMAC |
supramolecular activation cluster |
TandAb |
tandem diabody |
TBE |
target cell-biologic-effector cell (complex) |
TCB |
T-cell bispecifics |
TCR |
T-cell receptor |
TILs |
tumor infiltrating lymphocytes |
TME |
tumor microenvironment |
TRBA |
T-cell redirecting bispecific antibody |
TriKE |
trispecific killer engager |
TITAC |
trispecific T cell activating construct |
US-FDA |
United States Food and Drug Administration |